HER2-negative metastatic breast cancer patients receiving first-line docetaxel: Survival data and prognostic factors

被引：0

作者：

Deblock, M. ^{[1
]}

Esterni, B. ^{[1
]}

Tarpin, C. ^{[1
]}

Charaffe-Jauffret, E. ^{[1
]}

Extra, J. M. ^{[1
]}

Viens, P. ^{[1
]}

Goncalves, A. ^{[1
]}

机构：

[1] Inst Paoli Calmettes, Marseille, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1105

引用

页数：1

共 50 条

[21] Capecitabine after Anthracycline and Taxane Exposure in HER2-negative Metastatic Breast Cancer Patients: Response, Survival and Prognostic Factors [J].

Gilaberti, Marine ;

Bertucci, Francois ;

Esterni, Benjamin ;

Madroszyk, Anne ;

Tarpin, Carole ;

Jacquemier, Jocelyne ;

Extra, Jean-Marc ;

Viens, Patrice ;

Goncalves, Anthony .

ANTICANCER RESEARCH, 2011, 31 (03) :1079-1086

[22] Paclitaxel and bevacizumab in first-line treatment for HER2-negative metastatic breast cancer: single-center experience [J].

Lorenzo Livi ;

Pierluigi Bonomo ;

Icro Meattini ;

Gabriele Simontacchi ;

Daniela Greto ;

Isacco Desideri ;

Fiammetta Meacci ;

Vieri Scotti ;

Sara Cecchini ;

Jacopo Nori ;

Luis Jose Sanchez ;

Lorenzo Orzalesi ;

Fabiola Paiar ;

Gianpaolo Biti .

Medical Oncology, 2013, 30

[23] Paclitaxel and bevacizumab in first-line treatment for HER2-negative metastatic breast cancer: single-center experience [J].

Livi, Lorenzo ;

Bonomo, Pierluigi ;

Meattini, Icro ;

Simontacchi, Gabriele ;

Greto, Daniela ;

Desideri, Isacco ;

Meacci, Fiammetta ;

Scotti, Vieri ;

Cecchini, Sara ;

Nori, Jacopo ;

Sanchez, Luis Jose ;

Orzalesi, Lorenzo ;

Paiar, Fabiola ;

Biti, Gianpaolo .

MEDICAL ONCOLOGY, 2013, 30 (01)

[24] Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer [J].

Tamura, Kenji ;

Inoue, Kenichi ;

Masuda, Norikazu ;

Takao, Shintaro ;

Kashiwaba, Masahiro ;

Tokuda, Yutaka ;

Iwata, Hiroji ;

Yamamoto, Naohito ;

Aogi, Kenjiro ;

Saeki, Toshiaki ;

Nakayama, Takahiro ;

Sato, Nobuaki ;

Toyama, Tatsuya ;

Ishida, Takanori ;

Arioka, Hitoshi ;

Saito, Mitsue ;

Ohno, Shinji ;

Yamauchi, Hideko ;

Yamada, Kimito ;

Watanabe, Junichiro ;

Ishiguro, Hiroshi ;

Fujiwara, Yasuhiro .

CANCER SCIENCE, 2017, 108 (05) :987-994

[25] Prognostic factors for survival in metastatic breast cancer during first-line paclitaxel chemotherapy [J].

Nisman, B ;

Barak, V ;

Hubert, A ;

Kaduri, L ;

Lyass, O ;

Baras, M ;

Peretz, T .

ANTICANCER RESEARCH, 2003, 23 (2C) :1939-1942

[26] Polymorphism Analysis in the AVADO Randomised Phase III Trial of First-line Bevacizumab (BEV) Combined With Docetaxel in HER2-negative Metastatic Breast Cancer (mBC) [J].

Miles, D. W. ;

De Haas, S. L. ;

Romieu, G. ;

Chan, A. ;

Dirix, L. ;

Cortess, J. ;

Delmar, P. R. ;

Scherer, S. J. .

EUROPEAN JOURNAL OF CANCER, 2011, 47 :S176-S176

[27] Bevacizumab as first-line treatment in HER2-negative advanced breast cancer: pros and cons [J].

Sini, Valentina ;

Cassano, Alessandra ;

Corsi, Domenico ;

De Laurentiis, Michele ;

Gamucci, Teresa ;

Mauri, Mariella ;

Naso, Giuseppe ;

Roselli, Mario ;

Ruggeri, Enzo Maria ;

Tonini, Giuseppe ;

Vici, Patrizia ;

Zampa, Germano ;

Marchetti, Paolo .

TUMORI JOURNAL, 2016, 102 (05) :472-480

[28] Docetaxel-gemcitabine in patients with HER2-negative metastatic breast cancer pretreated with anthracyclines. [J].

Bautista Aragon, Y. L. ;

Pluma Jimenez, M. A. ;

Silva, A. J. ;

Perez, M. ;

Gutierrez, J. A. ;

Villalobos, R. ;

Rivera, S. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)

[29] Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer [J].

Salvador, J. ;

Manso, L. ;

de la Haba, J. ;

Jaen, A. ;

Ciruelos, E. ;

de Villena, M. C. ;

Gil, M. ;

Murias, A. ;

Galan, A. ;

Jara, C. ;

Bayo, J. ;

Baena, J. M. ;

Casal, J. ;

Mel, J. R. ;

Blancas, I. ;

Sanchez Rvira, P. .

CLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (02) :160-166

[30] Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer [J].

J. Salvador ;

L. Manso ;

J. de la Haba ;

A. Jaen ;

E. Ciruelos ;

M. C. de Villena ;

M. Gil ;

A. Murias ;

A. Galan ;

C. Jara ;

J. Bayo ;

J. M. Baena ;

J. Casal ;

J. R. Mel ;

I. Blancas ;

P. Sanchez Rvira .

Clinical and Translational Oncology, 2015, 17 :160-166

← 1 2 3 4 5 →